Compare F.N.B. Corporation Common Stock (FNB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Sanofi SA — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while Sanofi SA trades at $40.66 (market cap $96.38B). The key difference: Sanofi SA is far larger — about 16× F.N.B. Corporation Common Stock's market cap, and Sanofi SA pays the higher dividend (6.08%). Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| FNB | SNY | |
|---|---|---|
Market Cap | $6.03B | $96.38B |
Volume | 7,117,178 | 5,335,342 |
Sector | Financials | Health |
52-Week High | $19.49 | $52.34 |
52-Week Low | $14.65 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $10.52B | $115.67B |
Dividend Yield | 3.07% | 6.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Sanofi (SNY) trades at $39.12, down 1.56% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with $46.72B revenue, 16.72% net margin, and reasonable valuation (P/E 21.71). Recent expansion of the Regeneron immunology alliance worth up to $8B signals growth potential beyond Dupixent, though 2026 forecasts indicate profit margin compression to 8.09%.
SNY presents a mixed outlook with strong current execution offset by future margin pressures. The bullish analyst consensus (44% Buy) and expanding immunology pipeline provide upside catalysts, while patent expirations and competitive threats pose medium-term risks. Cash flow volatility and debt levels require monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
